GlassScriptPhysician profile
Cory Lynn Straub
NPI 1154634996
$6,951.80
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,106 · 2020: $399 · 2021: $1,394 · 2022: $1,357 · 2023: $2,427 · 2024: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,349 · Travel and Lodging: $1,299 · Education: $48.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,349.27 |
| Travel and Lodging | $1,298.58 |
| Education | $48.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,048.07 | 2023-2024 | Minimed 780g, Guardian Sensor (3) |
| Astrazeneca Pharmaceuticals LP | $683.87 | 2019-2022 | |
| Novo Nordisk INC | $663.52 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $479.05 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $403.45 | 2019-2023 | Jardiance, Glyxambi, Tradjenta |
| Sanofi-Aventis U.S. LLC | $373.56 | 2019-2023 | |
| Amgen INC. | $337.19 | 2019-2023 | Evenity, Prolia |
| Dexcom, INC. | $301.43 | 2019-2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $294.10 | 2019-2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $245.20 | 2021-2023 | |
| Corcept Therapeutics | $194.25 | 2019-2023 | Korlym |
| Tandem Diabetes Care, INC. | $180.87 | 2019-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Merck Sharp & Dohme LLC | $147.38 | 2019-2022 | |
| Abbvie INC. | $97.73 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $58.45 | 2021-2023 | Gvoke Hypopen |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $53.66 | 2022-2023 | Afrezza |
| Shire North American Group INC | $50.93 | 2019 | |
| Horizon Therapeutics Plc | $50.52 | 2023 | Tepezza |
| Regeneron Healthcare Solutions, INC. | $48.98 | 2019 | |
| Janssen Pharmaceuticals, INC | $36.86 | 2019-2020 | |
| Bigfoot Biomedical INC | $35.36 | 2022-2023 | Unity Diabetes Management System |
| Antares Pharma, INC. | $31.70 | 2022-2023 | Tlando, Nocdurna, Xyosted |
| Kowa Pharmaceuticals America, INC. | $29.89 | 2019-2021 | |
| Insulet Corporation | $29.20 | 2019-2022 | |
| Valeritas, INC. | $27.03 | 2019 | |
| Amryt Pharma Holdings LTD | $18.18 | 2022 | |
| Alexion Pharmaceuticals, INC. | $16.91 | 2021 | |
| Medtronic Minimed, INC. | $14.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cory Straub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.